Employer record · Alameda, CA · FY2022–FY2025

Scribe Therapeutics Inc.

    USCIS approval rateFY24–26 · 9 approved

    Certified LCAs
    8
    FY2024–FY2026
    USCIS approvals
    9
    6 new employment
    Denial rate
    10.0%
    FY2024–FY2026
    Median wage offered
    $136k
    certified LCAs

    Jobs not indexed yet

    Does Scribe Therapeutics Inc. sponsor H-1B visas?

    Yes — by its record, Scribe Therapeutics Inc. is a small-scale H-1B sponsor: it filed 8 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 9 USCIS H-1B petition approvals (6 for new employment). Its latest certified LCA in our data was decided May 14, 2025. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.

    Updated · DOL OFLC LCA disclosure + USCIS H-1B Employer Data Hub

    Filings by fiscal year

    Certified LCAs per U.S. government fiscal year (Oct–Sep) — 13 since FY2020; the slim bar is USCIS petition approvals (new + continuing), the bottom row their approval rate.

    Scribe Therapeutics Inc. certified LCAs by fiscal year
    Fiscal yearcertified LCAsUSCIS approvalsApproval rate
    FY2232100%
    FY2320–
    FY2467100%
    FY252267%

    Occupations sponsored

    Occupation (SOC)LCAsMedian wage
    Molecular and Cellular Biologists 19-10297$145k
    Biochemists and Biophysicists 19-10211$125k

    Most-filed job titles

    1. Scientist I4$136k
    2. Research Associate II2$96k
    3. Senior Data Scientist1$195k
    4. Principal Scientist1$166k

    LCAs per title and median wage offered.

    Where the jobs were

    1. California8 LCAs

    We haven't indexed Scribe Therapeutics' jobs yet

    We read jobs straight from employers' own career sites and haven't added Scribe Therapeutics' yet. Its H-1B record on this page comes from public DOL and USCIS data and is not affected.

    Also filed as

    • SCRIBE THERAPEUTICS INC (USCIS)
    • Scribe Therapeutics Inc. (LCA)

    Scribe Therapeutics Inc. H-1B: questions people ask

    Does Scribe Therapeutics Inc. sponsor H-1B visas?

    Yes — by its record, Scribe Therapeutics Inc. is a small-scale H-1B sponsor: it filed 8 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 9 USCIS H-1B petition approvals (6 for new employment). Its latest certified LCA in our data was decided May 14, 2025. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.

    Is Scribe Therapeutics Inc. still sponsoring H-1B in 2026?

    Scribe Therapeutics Inc. had 0 certified LCAs in FY2026 (Oct 2025–Sep 2026), fewer than the 2 in FY2025. The latest one in our data was decided May 14, 2025. An LCA is filed before a petition, so it shows recent intent to hire on H-1B, not a hire.

    How many H-1B petitions does Scribe Therapeutics Inc. get approved?

    USCIS recorded 9 approvals (6 for new employment, the rest continuing employment such as extensions and transfers) and 1 denials for Scribe Therapeutics Inc. in FY2024–FY2026 — a denial rate of 10.0%. Source: USCIS H-1B Employer Data Hub (first decisions).

    What is the H-1B salary at Scribe Therapeutics Inc.?

    The median wage offered on Scribe Therapeutics Inc.'s certified LCAs in FY2024–FY2026 was $136k a year. By job title: Scientist I $136k (4 LCAs), Research Associate II $96k (2 LCAs) and Senior Data Scientist $195k (1 LCAs). LCA wages are the pay the employer attested to; actual pay can be higher.

    Which jobs does Scribe Therapeutics Inc. sponsor for H-1B?

    Its certified LCAs in FY2024–FY2026 were mostly for Molecular and Cellular Biologists (7) and Biochemists and Biophysicists (1).

    Where are Scribe Therapeutics Inc.'s H-1B jobs?

    By worksite on its certified LCAs (FY2024–FY2026): California (8).

    Is Scribe Therapeutics Inc. an H-1B dependent employer?

    No — its recent LCAs do not declare it H-1B dependent.

    Does Scribe Therapeutics Inc. have open jobs?

    We read jobs straight from employers' own career sites and haven't added Scribe Therapeutics' yet.